<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736811</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-1810-037-977</org_study_id>
    <nct_id>NCT03736811</nct_id>
  </id_info>
  <brief_title>Nonabsorbable Versus Absorbable Sutures for Anterior Colporrhaphy</brief_title>
  <official_title>Nonabsorbable Versus Absorbable Sutures for Anterior Colporrhaphy: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this is to compare surgical outcomes of anterior colporrhaphy using
      nonabsorbable sutures with anterior colporrhaphy using absorbable sutures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a prospective, randomized trial conducted with the aim to determine superiority
      of anterior colporrhaphy using nonabsorbable sutures over absorbable sutures with regard to
      the primary outcome. Participants will undergo reconstructive surgery for prolapse, including
      anterior colporrhaphy using the assigned suture materials under general or spinal anesthesia.
      The anterior colporrhaphy will be performed in a traditional manner with midline plication of
      the fibromuscular layer using either 2-0 nonabsorbable (polyester or polypropylene; Ethicon,
      Somerville, NJ) or absorbable (polyglactin 910 or polydioxanone; Ethicon) sutures.
      Concomitant procedures will be performed as intended prior to surgery. Women with a uterus in
      situ will undergo hysterectomy and all women will receive an apical suspension procedure,
      including uterosacral ligament suspension, sacrospinous ligament fixation, and iliococcygeal
      suspension, according to the preference of surgeon. Posterior colporrhaphy and incontinence
      surgery will also be performed, if indicated (i.e. women with Bp ≥-1 or documented urodynamic
      stress incontinence).

      Enrollment, treatment and data collection will be standardized by all sites. The study will
      be a single-blind study, as it is impossible to blind the study surgeon for the surgical
      procedure to which the subject in assigned. However, all outcomes assessors and the subjects
      will be blinded to the treatment assignment. Postoperative follow-up will take place after 5
      weeks, 6 months and 12 months. Patients will undergo a standard gynecological examination
      including POPQ and fill in questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical success</measure>
    <time_frame>One year after surgery</time_frame>
    <description>defined as the absence of all of the following: (1) anterior vaginal descent beyond the hymen (POPQ point Ba&gt;0); (2) presence of vaginal bulge symptoms (affirmative response to the question 3 from the Pelvic Floor Distress Inventory-20 (&quot;do you usually have a bulge or something falling out that you can see or feel in your vaginal area?&quot;; (3) re-treatment for recurrent anterior vaginal wall prolapse by either surgery or pessary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of anterior vaginal descent beyond the hymen</measure>
    <time_frame>One year after surgery</time_frame>
    <description>POPQ point Ba&gt;0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of vaginal bulge symptoms</measure>
    <time_frame>One year after surgery</time_frame>
    <description>an affirmative response to the question 3 from PFDI-20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of re-treatment for recurrent anterior vaginal wall prolapse</measure>
    <time_frame>One year after surgery</time_frame>
    <description>by either surgery or pessary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of suboptimal anatomical outcome in each compartment</measure>
    <time_frame>One year after surgery</time_frame>
    <description>POPQ point Ba, C, or Bp ≥-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of POPQ values</measure>
    <time_frame>From baseline to 1 year after surgery</time_frame>
    <description>point Ba, C, Bp and TVL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of PFDI-20 scores</measure>
    <time_frame>From baseline to 1 year after surgery</time_frame>
    <description>The PFDI-20 is a valid and reliable condition-specific quality-of-life questionnaires for women with pelvic floor disorders. It has 20 items and 3 scales (Pelvic Organ Prolapse Distress Inventory, Colorectal-Anal Distress Inventory and Urinary Distress Inventory). Each scale is scored from 0 to 100; higher scores indicate greater symptom burden.
The PFDI-20 total score is obtained by adding the scores from the 3 scale scores together (0-300).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of adverse events related with anterior colporrhaphy</measure>
    <time_frame>From baseline to 1 year after surgery</time_frame>
    <description>intraoperative- bladder injury, ureteral obstruction, massive bleeding
postoperative- hematoma, vesico-vaginal fistula, ureteral obstruction, urinary tract infection, incomplete bladder emptying, overactive bladder or stress incontinence symptoms, suture erosion, vaginal wound dehiscence, infection or granulation tissue, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Absorbable suture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyglactin 910 [Vicryl] or polydioxanone [PDS II] sutures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonabsorbable suture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyester [Ethibond Excel] or polypropylene [Prolene] sutures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polyglactin 910 or polydioxanone</intervention_name>
    <description>Vicryl or PDS II</description>
    <arm_group_label>Absorbable suture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polyester or polypropylene</intervention_name>
    <description>Ethibond Excel or prolene</description>
    <arm_group_label>Nonabsorbable suture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anterior vaginal descent beyond the hymen (i.e. POPQ Ba&gt;0)

          -  Vaginal bulge symptoms (i.e. an affirmative response to the question 3 from the
             PFDI-20)

          -  Reconstructive surgery is planned

        Exclusion Criteria:

          -  Recurrent anterior vaginal wall prolapse

          -  Reconstructive surgery using mesh or obliterative surgery for prolapse is planned

          -  Known pelvic malignancy

          -  Systemic glucocorticoid or immunosuppressant treatment

          -  Subject wishes to retain her uterus

          -  Subject is unable and unwilling to participate in
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung Jae Jeon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myung Jae Jeon, MD, PhD</last_name>
    <phone>+82-2-2072-1916</phone>
    <email>jeonmj@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Myung Jae, Jeon</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung Jae Jeon, MD, PhD</last_name>
      <email>jeonmj@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Myung Jae Jeon</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

